By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: InSite Vision Is Developing Treatment For Common Eye Disease Blepharitis, For Which There Is Currently No Approved Treatment
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > InSite Vision Is Developing Treatment For Common Eye Disease Blepharitis, For Which There Is Currently No Approved Treatment
Technology

InSite Vision Is Developing Treatment For Common Eye Disease Blepharitis, For Which There Is Currently No Approved Treatment

HerinaAyot
HerinaAyot
Share
3 Min Read
SHARE

InSite Vision Inc. (OTCBB:INSV) has reached an agreement with the U.S.

InSite Vision Inc. (OTCBB:INSV) has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of a Phase 3 clinical trial of AzaSite Plus and DexaSite in patients with blepharitis.

Blepharitis, also known as lid margin disease, is a very common eye disease in the United States and internationally. Characterized by inflammation of the eyelid, blepharitis is a chronic and recurring condition for which there is currently no FDA-approved treatment. The acute flare-ups of this disease can be painful and extremely irritating.

The DOUBle (Dual Ophthalmic agents Used in Blepharitis) study will seek to enroll 900 patients suffering from moderate-to-severe blepharitis in a four-arm trial designed to evaluate both product candidates simultaneously. An SPA is a written agreement with the FDA that the study design and planned analysis of the sponsor’s Phase 3 clinical trial adequately addresses the objectives necessary to support a regulatory submission.

More Read

What Are Sensors And How Are They Used In Health?
Employee Devices + Mobile Healthcare Information = a Quiet, Perfect Storm
Speaking from the Heart with Patient Empowerment Network
September 26-28 AdvaMed 2011
Mobility Matters in Physician Satisfaction with EHR Solutions

InSite Vision is developing two Phase 3 product candidates formulated with the company’s proprietary DuraSite drug delivery platform for the treatment of blepharitis. AzaSite Plus, combines dexamethasone with the antibiotic AzaSite in DuraSite for the treatment of acute and chronic blepharitis. DexaSite, which combines dexamethasone with DuraSite, is intended to rapidly reduce inflammation in non-bacterial blepharitis.

InSite’s DuraSite sustained delivery technology is a patented synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and can be customized for delivering a wide variety of potential drug candidates. InSite vision is also applying DuraSite to multiple other clinical- and preclinical-stage product candidates to create a portfolio of novel ophthalmic products.

The study will utilize a proprietary quality of life questionnaire developed by InSite Vision in collaboration with leading clinicians and academic experts and the FDA to assess patient treatment experience and longitudinal comfort levels.

“It has been estimated that 34 million people in the United States suffer from blepharitis for which there is currently no approved pharmaceutical treatment,” said Timothy Ruane, Chief Executive Officer of InSite Vision.  “Based on our clinical experience with AzaSite Plus and DexaSite, we believe that the design of the DOUBle Phase 3 program provides us with a unique opportunity to advance two promising products for the treatment of this disease in a single study.”

 

TAGGED:blepharitismedical technology
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025
AI in Healthcare
AI in Healthcare: Technology is Transforming the Global Landscape
Global Healthcare Policy & Law Technology
October 1, 2025
Choosing the Right Swimwear for Health and Safety
News
September 30, 2025
sports concussions
Concussion In Sports: How Common They Are And What You Need To Know
Infographics
September 28, 2025

You Might also Like

6 Questions Hospital CIOs and IT Directors Should Be Asking Vendors

January 12, 2011
EHR technology
BusinessHospital AdministrationTechnology

Boosting Hospital Efficiency With The Right EMR Systems

March 28, 2024
mHealth
eHealthTechnology

What To Know About How mHealth Apps Benefit Heart Patients

July 8, 2019

Monash Health Benefits from a Vendor-Neutral Archive

April 24, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?